Investor That Backed Moderna Raises $3.6B For AI-driven Biotech Ventures
Investor That Backed Moderna Raises $3.6B For AI-driven Biotech Ventures
In a recent development, Flagship Pioneering, the venture capital firm known for backing Moderna (NASDAQ:MRNA) has successfully secured a whopping $3.6 billion in funding.
近期，为Moderna（纳斯达克：MRNA）提供支持的风投公司Flagship Pioneering已成功获得360亿美元的资金。
What Happened: Flagship Pioneering has raised $2.6 billion for its eighth fund and an additional $1 billion for parallel funds. These parallel funds will be invested in specific sectors such as diagnostics or therapeutics. The venture firm is also planning to raise more funds for its eighth fund later this year. The funds are intended to launch a series of new biotech companies that will harness the power of generative artificial intelligence for drug discovery, The Financial Times reported on Wednesday.
事件经过：Flagship Pioneering已为其第8号基金筹集到260亿美元，并额外筹得100亿美元用于并行基金。这些并行基金将投资于诊断或治疗等特定领域。该风险投资公司还计划于今年晚些时候为第8号基金筹集更多资金。《金融时报》周三报道称，这些资金旨在启动一系列新的生物技术公司，利用生成式人工智能技术进行药物研发。
Noubar Afeyan, the founder of Flagship, stated that a significant part of the investments from the eighth fund will be directed towards platforms that employ AI in innovative ways for drug development. The firm is considering ideas like using AI to create novel chemical materials for medicines and automating hypothesis generation for scientists.
Flagship的创始人Noubar Afeyan表示，第8号基金的很大一部分投资将用于采用创新方式利用人工智能平台进行药物开发。该公司正在考虑使用人工智能来创建新型化学物质以用于药品，并自动化为科学家生成假设等想法。
Why It Matters: Flagship's successful fundraising signifies a positive trend for venture investment in biotech. This sector has been recovering from a downturn triggered by the end of a pandemic-induced boom and a series of interest rate hikes. Flagship's investment strategy is increasingly focusing on biotechs developing individual drugs, with at least a quarter of investments from its last fund deployed through its Pioneering Medicines arm.
重要性：Flagship的成功筹资预示着风险投资在生物技术领域的积极趋势。该领域已经从疫情引发的繁荣结束和一系列利率上调引发的低迷中恢复过来。Flagship的投资策略越来越注重开发个体药物的生物技术公司，其上一个基金至少有四分之一的投资通过其先锋医药部署。
In April, the global AI in healthcare market size was valued at $20.9 billion and is expected to reach $148.4 billion by 2029. This indicates a growing interest in AI-driven healthcare solutions.
今年4月，全球人工智能医疗市场价值为209亿美元，并预计到2029年将达到1484亿元。这表明AI驱动的医疗解决方案受到越来越多的关注。
Moreover, there is growing investment in healthtech sector. For instance, in June, SoftBank Group Corp (OTC:SFTBF) announced a joint venture with Tempus AI Inc (NASDAQ:TEM) to enhance precision medicine in Japan using AI.
此外，对于健康科技领域有越来越多的投资。例如，在6月，SoftBank Group Corp（场外交易：SFTBF）宣布与Tempus AI Inc（纳斯达克：TEM）合作，利用人工智能增强日本的精准医疗。
- Former Mike Pence Staffer Dismisses Trump's Attempts To Distance Himself From 'Project 2025' — 'Preposterous If You Look At The Collaborators'
- 前副总统助理否认特朗普试图与“2025计划”保持距离——“如果您看看合作者，这是荒谬的”
Image via Shutterstock
图片来自shutterstock。
This story was generated using Benzinga Neuro and edited by Pooja Rajkumari
本报道使用Benzinga Neuro生成，并由Pooja Rajkumari编辑